1. Patient disposition over the 52-week study period
Patient disposition over the 52-week study period. *Patients did not meet study inclusion criteria (patient may have more than one reason), including 62 with CRP <2.0 mg/dL or ESR <28 mm/hour ESR, 26 ACPA-negative and 20 with ALT >2×ULN.
Patient disposition over the 52-week study period. *Patients did not meet study inclusion criteria (patient may have more than one reason), including 62 with CRP <2.0 mg/dL or ESR <28 mm/hour ESR, 26 ACPA-negative and 20 with ALT >2×ULN. ACPA, anti-citrullinated protein antibody; ALT, alanine transaminase; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; MTX, methotrexate; ULN, upper limit of normal.
Tsukasa Matsubara et al. RMD Open 2018;4:e000813
Copyright © BMJ Publishing Group & EULAR. All rights reserved.